S. Charnick

发表

Physiologically based pharmacokinetic modeling as a tool for drug development

J. Nedelman, Hitoshi Sato, W. Niederberger, 1995, Journal of pharmacokinetics and biopharmaceutics.

Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.

P. Sonneveld, A. Vekhoff, A. Faussat, 1996, Leukemia.

Description of blood pressure changes in patients beginning cyclosporin A therapy.

J. Nedelman, S. Charnick, M. Moore, 1997, Therapeutic drug monitoring.

Validation of a Limited Sampling Model to Determine Etoposide Area Under the Curve

B. Sikic, T. Synold, S. Charnick, 1997, Pharmacotherapy.

Pharmacokinetics of SDZ 64‐412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat

F. Tse, A. Karara, S. Charnick, 1994, Biopharmaceutics & drug disposition.

Mathematical analysis of cell-target encounter rates in three dimensions. Effect of chemotaxis.

D. Lauffenburger, S. Charnick, 1987, Biophysical journal.

Interaction of cyclosporin derivatives with the ATPase activity of human P‐glycoprotein

T. Tsuruo, D. Cohen, M. Naito, 1997, British journal of pharmacology.

Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor.

E. Mueller, S. Charnick, W. Robinson, 1998, Transplantation Proceedings.

Efficacy and Pharmacokinetics of Two Formulations of Cyclosporine A in Patients with Psoriasis

J. Nedelman, K. Simpson, A. Karara, 1995, Journal of clinical pharmacology.

Computer simulations of cell-target encounter including biased cell motion toward targets: single and multiple cell-target simulations in two dimensions.

S B Charnick, E S Fisher, D A Lauffenburger, 1991, Bulletin of mathematical biology.

The hydration of proteins in nearly anhydrous organic solvent suspensions

M. Paulaitis, S. Charnick, J. Mcminn, 1993, Biopolymers.